These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New and emerging strategies for improving levodopa treatment. Tolosa ES; Valldeoriola F; Martí MJ Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259 [TBL] [Abstract][Full Text] [Related]
5. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease. Rinne UK J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601 [TBL] [Abstract][Full Text] [Related]
7. Advances in the delivery of treatments for Parkinson's disease. Johnston TH; Fox SH; Brotchie JM Expert Opin Drug Deliv; 2005 Nov; 2(6):1059-73. PubMed ID: 16296809 [TBL] [Abstract][Full Text] [Related]
8. Treatment of levodopa-induced motor complications. Stocchi F; Tagliati M; Olanow CW Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681 [TBL] [Abstract][Full Text] [Related]
9. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Olanow CW; Obeso JA Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513 [TBL] [Abstract][Full Text] [Related]
10. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A; Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107 [TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease therapy: treatment of early and late disease. Jankovic J Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303 [TBL] [Abstract][Full Text] [Related]
12. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease. Youdim MB J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263 [TBL] [Abstract][Full Text] [Related]
13. Levodopa: past, present, and future. Hauser RA Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449 [TBL] [Abstract][Full Text] [Related]
14. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
16. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon. Tse W J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614 [TBL] [Abstract][Full Text] [Related]
17. Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263 [TBL] [Abstract][Full Text] [Related]